Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

FINAL FOLLOW UP CALLS COMPLETED

Final follow up calls have been completed, and the Coordinating Centre in Oxford has now received the final NHS linkage data for all LENS participants. Results for the trial will emerge in mid-2024.

 

FINAL FOLLOW UP CALLS FROM JULY TO SEPTEMBER 2023

When we designed LENS, we knew that the trial needed to include enough participants and continue for long enough to reliably tell us whether treatment with fenofibrate is beneficial—in other words, if fenofibrate reduces the number of people with diabetic retinopathy who go on to develop significant eye disease. The trial will continue until the second half of 2023 to achieve this.

From 17 July 2023, participants will have their final LENS call with one of the research nurses. A few weeks before this, we will also send participants the two paper questionnaires (about vision and quality of life) by mail to complete one last time.

 

INTERNATIONAL CLINICAL TRIALS DAY 2022

May 20th is International Clinical Trials Day. This is the anniversary of the date in 1747 when James Lind, a  surgeon's mate on the HMS Salisbury, started what is often considered the first clinical trial, testing whether various treatments might be beneficial for sailors suffering from scurvy. It is a timely reminder of the value of randomised trials such as LENS. Some of the important features of trials are discussed at the following website:

https://www.ndph.ox.ac.uk/news/clinical-trials-day-2022 

 

RECRUITMENT INTO THE LENS TRIAL IS COMPLETE!

Congratulations to NHS Forth Valley who enrolled the final participant to join the LENS trial (on 27th July 2021). Our amazing sites have randomized 1151 participants between them across all mainland NHS Scotland Health Boards.

 

THE CHALLENGES OF CONDUCTING CLINICAL TRIALS DURING A PANDEMIC

You may be interested to read the article by Dr Caroline Wood (University of Oxford) which describes some of the challenges that have arisen conducting clinical trials of treatments for chronic disease in the time of COVID-19. Various features of the LENS trial, and the heroic efforts of the study team in Oxford and across Scotland, have meant that the study has continued to progress well despite these difficult circumstances. You can find the article at: 

https://www.ndph.ox.ac.uk/longer-reads/a-tale-of-three-trials-the-impact-of-covid-19-on-clinical-research

 

questionnaires on visual function and quality of life

Participants who have been taking part in LENS for over 2 years will receive a couple of questionnaires in the post. The first questionnaire (called the VFQ-25) asks about your vision. The second questionnaire (called the EQ-5D) asks about your quality of life. These are the same questionnaires that you completed at the very start of the trial.

The information that we collect in these forms is very important to the trial, and we greatly appreciate you taking the time to complete them and send them back to us by FREEPOST. If you have any questions about how to complete either of the questionnaires, please do not hesitate to give us a call. Thank you for your ongoing support for LENS.

 

 

Newsletters

iconfinder_24_2133056.png

 

 Insight - LENS trial newsletter Volume 1

                                                                                                            

iconfinder_24_2133056.png

 

 Insight - LENS trial newsletter Volume 2

                                                                                                                                                     

 

 

Link to newsletter

 

Insight - LENS trial  newsletter Volume 3

 

Link to newsletter

Insight- LENS trial newsletter Volume 4